Forever Labs will dedicate resources to continue pioneering stem cell research breakthroughs and accelerate brand development.
Founded in 2015, Forever Labs is transforming the healthcare industry by preserving healthy stem cells for future therapies that combat age-related diseases, as well as aging itself.
Its proprietary procedure involves a certified Forever Labs physician collecting one's mesenchymal stem cells (MSCs), which have the ability to stimulate tissues to grow and repair themselves when most needed.
After a brief outpatient procedure, the stem cells are cryogenically frozen and safely stored agnostically in an FDA-compliant clinical-grade biorepository until needed.
Forever Labs was created to preserve healthy stem cells to later rejuvenate one's MSC population to significantly delay the onset of those age-related diseases and extend a healthy lifespan.
Pharming receives FDA priority review for leniolisib in children with APDS
Renalytix submits CE Mark application for kidneyIntelX.dkd in Europe
Vicore Pharma's buloxibutid receives orphan drug designation in Japan
Novartis to launch US direct-to-patient platform for Cosentyx
Genmab to acquire Merus in USD8bn all-cash deal
Polarean Imaging signs new supply agreementwith UVA Health for clinical Xenon MRI
Genmab to acquire Merus in USD8bn deal to strengthen oncology pipeline
Sen-Jam Pharmaceutical and KVK Tech complete final development deliverables for SJP-002C